The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study.
Magnus B PetersenRebekka L HansenAlexander EgebergTanja S JørgensenJoseph Frank MerolaLaura C CoatesLars Erik KristensenPublished in: Rheumatology advances in practice (2023)
The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.